Top 5 Undervalued Biotech Companies (February 2023)

The biotech sector had suffered a steep decline by the end of 2021. While it is far from recovered, this generalized “Biotech Rout’ have also put the stock of individual attractive company under their real value.

So, what are the most undervalued biotech companies in early 2023?

Evaluation Criterion

If there is one investment sector that does not yield well to purely mathematical analysis, it is biotech. This is because the value of a company can be highly reliant on future innovations. And such potential will not be apparent at first on a balance sheet or a cash flow statement.

This is very different from, let’s say, finding undervalued utilities or industrial companies. These companies have relatively predictable income and costs. So, looking solely at the P/E ratio or free cash flow is a good way to find which might be undervalued.

This is not the same for biotech stocks. Most of the time, biotech stocks will have fully priced in the incoming new drugs way before it shows in the revenues. So, the task of finding undervalued biotech stocks cannot rely on quantitative factors.

Instead, we used a more subjective (but more relevant) mix of:

• A good quality pipeline of innovative drugs.
• A good track record of R&D achievement or the backup of larger partners.
• A stock price that has declined due to the sector rout but not triggered by bad news on clinical trials or commercialization potential.
• If possible, good financial metrics like earnings and cash flows.
  • Or at least a good cash balance, reducing the risk of dilution.

1. CRISPR Therapeutics

(CRSP )